Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

N-803 Plus Intravesical BCG Produces 57% DFS in BCG-Unresponsive Papillary Bladder Cancer

October 20th 2021

Intravesical Bacillus Calmette–Guérin in combination with N-803 resulted in a 12-month disease-free survival rate of 57% in patients with BCG-unresponsive high-grade papillary non–muscle invasive bladder cancer, meeting the primary end point for cohort B of the phase 2/3 QUILT 3.032 trial.

UGN-102 May Provide Alternative to Repetitive Surgery in Low-Grade Intermediate-Risk NMIBC

October 19th 2021

Non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 produced significant, durable responses in those with low-grade intermediate-risk non–muscle invasive bladder cancer.

Expanding Armamentarium Underscores the Importance of Close Monitoring in Urothelial Cancer

October 12th 2021

Evan Y. Yu, MD, provided insight into treatment sequencing for patients with metastatic urothelial carcinoma, considerations for treatment decisions, and emerging therapies in the paradigm. 

Dr. Chatzkel on the Emergence of Novel Therapies in Metastatic Urothelial Cancer

October 6th 2021

Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.

Enfortumab Vedotin Challenges Standard of Care in Urothelial Carcinoma

October 5th 2021

Two indications have been granted by the FDA to the Nectin-4directed antibody, enfortumab vedotin-ejfv, marking a shift in the treatment landscape for patients with advanced urothelial carcinoma.

NICE Recommends Atezolizumab for Advanced Urothelial Cancer

September 30th 2021

The National Institute for Clinical Excellence has issued final guidance supporting the use of atezolizumab for patients with treatment-naïve, PD–L1–positive locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin.

Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer

September 30th 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

September 14th 2021

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

September 13th 2021

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

UGN-101 Induction Produces Durable Responses in Low-Grade Upper Tract Urothelial Carcinoma

September 13th 2021

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.

Panvac Plus BCG Does Not Significantly Delay Recurrence in Advanced NMIBC

September 13th 2021

The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Avelumab Plus BCG Induction Shows Favorable Tolerability in BCG-Unresponsive NMIBC

September 13th 2021

The addition of avelumab to Bacillus Calmette-Guerin induction therapy appeared to be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials

September 13th 2021

Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.

Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPH

September 12th 2021

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Dr. Williams on the Rationale for the SunRISE-2 Trial in Muscle-Invasive Bladder Cancer

September 12th 2021

Stephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.

Nadofaragene Firadenovec Sustains Efficacy in Advanced NMIBC in Longer-Term Follow-Up

September 11th 2021

Nadofaragene firadenovec, a novel intravesical gene therapy for patients with bacillus Calmette-Guérin unresponsive non–muscle invasive bladder cancer, demonstrated sustained durability according to findings from 2 cohorts of a phase 3 study.

Durvalumab/Vicineum Combo Shows Early Safety, Activity in High-Grade NMIBC

September 11th 2021

The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.

TAR-200/Cetrelimab Under Investigation in Muscle-Invasive Bladder Cancer

September 11th 2021

TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.

N-803/BCG Combo Shows Promising Responses, Tolerability in BCG-Unresponsive Bladder Cancer

September 10th 2021

Bacille Calmette-Guérin (BCG) plus N-803 yielded promising responses and an encouraging safety profile in patients with BCG-unresponsive, non-muscle invasive bladder cancer carcinoma in situ.

Elevated Antibody Titers May Predict Nadofaragene Firadenovec Durability in BCG-Unresponsive NMIBC

September 10th 2021

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec for the treatment of patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.